Shopping Cart 0
Cart Subtotal
AED 0

Cushing's Syndrome - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Cushing's Syndrome-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome-Pipeline Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) pipeline landscape.

Cushing syndrome occurs due to abnormally high levels of the hormone cortisol. The most common cause is overuse of corticosteroid medications. Symptoms of this condition are obesity, glucose intolerance, muscle weakness, bone loss, cognitive dysfunction, depression, and increased urination. Other causes include a pituitary gland tumor and ectopic ACTH syndrome. Treatment includes surgery and medications to control excessive production of cortisol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cushing's Syndrome-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cushing's Syndrome (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cushing's Syndrome (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cushing's syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 2 respectively.

Cushing's Syndrome (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cushing's Syndrome (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cushing's Syndrome (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cushing's Syndrome (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cushing's Syndrome (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cushing's Syndrome (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cushing's Syndrome-Overview

Cushing's Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cushing's Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cushing's Syndrome-Companies Involved in Therapeutics Development

Angion Biomedica Corp

AstraZeneca Plc

Corcept Therapeutics Inc

Diurnal Group Plc

ElexoPharm GmbH

Hybrigenics SA

Millendo Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Reset Therapeutics Inc

Strongbridge Biopharma plc

Cushing's Syndrome-Drug Profiles

ANG-3563-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing's Syndrome and Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4017-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBX-96819-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nevanimibe hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relacorilant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CYP11B1 for Cushing's Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease and Psychological Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cushing's Syndrome-Dormant Projects

Cushing's Syndrome-Product Development Milestones

Featured News & Press Releases

Apr 04, 2018: SteroTherapeutics Receives FDA Orphan-Drug Designation

Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's syndrome

Mar 20, 2018: Strongbridge Biopharma Announces Issuance of Patent for RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome

Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis

Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial

Jan 18, 2018: Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome

Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome

Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome

Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017

Nov 02, 2016: Millendo Therapeutics to present data on ATR-101 program at Society for Endocrinology British Endocrine Societies Conference

May 31, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology

Apr 28, 2016: Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers

Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society's 2016 Annual Conference

Dec 07, 2015: Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome

Oct 13, 2015: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cushing's Syndrome-Pipeline by Angion Biomedica Corp, H1 2018

Cushing's Syndrome-Pipeline by AstraZeneca Plc, H1 2018

Cushing's Syndrome-Pipeline by Corcept Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Diurnal Group Plc, H1 2018

Cushing's Syndrome-Pipeline by ElexoPharm GmbH, H1 2018

Cushing's Syndrome-Pipeline by Hybrigenics SA, H1 2018

Cushing's Syndrome-Pipeline by Millendo Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Novartis AG, H1 2018

Cushing's Syndrome-Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Cushing's Syndrome-Pipeline by Reset Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Strongbridge Biopharma plc, H1 2018

Cushing's Syndrome-Dormant Projects, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cushing's Syndrome Therapeutic Products under Development, Key Players in Cushing's Syndrome Therapeutics, Cushing's Syndrome Pipeline Overview, Cushing's Syndrome Pipeline, Cushing's Syndrome Pipeline Assessment


Companies

Cushing's Syndrome - Companies Involved in Therapeutics Development

Angion Biomedica Corp

Company Profile

Company Profile Title

Cushing's Syndrome-Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome-Pipeline Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) pipeline landscape.

Cushing syndrome occurs due to abnormally high levels of the hormone cortisol. The most common cause is overuse of corticosteroid medications. Symptoms of this condition are obesity, glucose intolerance, muscle weakness, bone loss, cognitive dysfunction, depression, and increased urination. Other causes include a pituitary gland tumor and ectopic ACTH syndrome. Treatment includes surgery and medications to control excessive production of cortisol.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cushing's Syndrome-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cushing's Syndrome (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cushing's Syndrome (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cushing's syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 2 respectively.

Cushing's Syndrome (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cushing's Syndrome (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Cushing's Syndrome (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Cushing's Syndrome (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cushing's Syndrome (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cushing's Syndrome (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cushing's Syndrome-Overview

Cushing's Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cushing's Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cushing's Syndrome-Companies Involved in Therapeutics Development

Angion Biomedica Corp

AstraZeneca Plc

Corcept Therapeutics Inc

Diurnal Group Plc

ElexoPharm GmbH

Hybrigenics SA

Millendo Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Reset Therapeutics Inc

Strongbridge Biopharma plc

Cushing's Syndrome-Drug Profiles

ANG-3563-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing's Syndrome and Cushing Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4017-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBX-96819-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nevanimibe hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relacorilant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CYP11B1 for Cushing's Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease and Psychological Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cushing's Syndrome-Dormant Projects

Cushing's Syndrome-Product Development Milestones

Featured News & Press Releases

Apr 04, 2018: SteroTherapeutics Receives FDA Orphan-Drug Designation

Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's syndrome

Mar 20, 2018: Strongbridge Biopharma Announces Issuance of Patent for RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome

Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis

Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial

Jan 18, 2018: Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome

Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing's Syndrome

Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome

Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017

Nov 02, 2016: Millendo Therapeutics to present data on ATR-101 program at Society for Endocrinology British Endocrine Societies Conference

May 31, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology

Apr 28, 2016: Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing's Syndrome and Solid-Tumor Cancers

Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society's 2016 Annual Conference

Dec 07, 2015: Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome

Oct 13, 2015: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cushing's Syndrome-Pipeline by Angion Biomedica Corp, H1 2018

Cushing's Syndrome-Pipeline by AstraZeneca Plc, H1 2018

Cushing's Syndrome-Pipeline by Corcept Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Diurnal Group Plc, H1 2018

Cushing's Syndrome-Pipeline by ElexoPharm GmbH, H1 2018

Cushing's Syndrome-Pipeline by Hybrigenics SA, H1 2018

Cushing's Syndrome-Pipeline by Millendo Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Novartis AG, H1 2018

Cushing's Syndrome-Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Cushing's Syndrome-Pipeline by Reset Therapeutics Inc, H1 2018

Cushing's Syndrome-Pipeline by Strongbridge Biopharma plc, H1 2018

Cushing's Syndrome-Dormant Projects, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cushing's Syndrome Therapeutic Products under Development, Key Players in Cushing's Syndrome Therapeutics, Cushing's Syndrome Pipeline Overview, Cushing's Syndrome Pipeline, Cushing's Syndrome Pipeline Assessment


Companies

Cushing's Syndrome - Companies Involved in Therapeutics Development

Angion Biomedica Corp